Quinazoline Derivatives as Potential Therapeutic Agents in Breast Cancer, Cervical Cancer, and Ovarian Cancer Therapy

Abstract

Quinazoline derivatives have garnered attention as potential therapeutic candidates in breast cancer, cervical cancer, and ovarian cancer treatment due to their diverse molecular structures and promising pharmacological activities. This review aims to comprehensively explore the mechanisms of action, pharmacological profiles, and current research landscape of quinazoline derivatives in oncology. A systematic literature review was performed to collect studies relevant to the application of quinazoline derivatives in cancer therapy. Searches were conducted in databases such as PubMed, Scopus, and Web of Science using keywords related to quinazoline derivatives, breast cancer, cervical cancer, ovarian cancer, pharmacology, preclinical studies, and clinical trials.Quinazoline derivatives exhibit a wide range of structural diversity, contributing to their versatile pharmacological activities in cancer therapy. Mechanistically, these derivatives interact with key molecular targets complicated in cancer cell propagation, apoptosis, angiogenesis, and metastasis. Preclinical observations have demonstrated their efficacy in inhibiting tumor growth and metastatic spread across various cancer models. Clinical trials have shown promising results regarding their safety profiles and therapeutic efficacy in cancer patients, although challenges such as pharmacokinetic limitations and resistance mechanisms persist. In conclusion, quinazoline derivatives are promising compounds with significant potential in breast, cervical, and ovarian cancer therapy. Their multifaceted mechanisms of action and encouraging preclinical and clinical data underscore their role as valuable candidates for further development as anticancer agents. Addressing current challenges and exploring innovative research avenues, such as combination therapies and targeted delivery systems, are crucial steps towardyoking the full beneficialprobability of quinazoline derivatives in oncology.